Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of prod...

Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.

Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to ​focus on a fresh disappointment in U.S. patient volumes ‌and the management's decision to merely confirm, not raise, the full-year guidance.

Fresenius Medical Care on Monday reported second-quarter operating income well ahead of ​market expectations and reaffirmed its full-year outlook, ‌as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient ​treatment volumes.

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's g...

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be compl...